- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00073385
Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
A Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients With Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Rationale: Pivanex is a histone deacetylase inhibitor that induces tumor differentiation and/or apoptosis. Pivanex has been well tolerated in clinical trials and has shown preliminary evidence of efficacy in patients with non-small cell lung cancer. Docetaxel is an approved drug for second-line treatment of non-small cell lung cancer. Preclinical studies indicate that the combination of Pivanex and docetaxel is synergistic.
Purpose: This open-label randomized trial will evaluate whether combination therapy with Pivanex and docetaxel provides clinical benefit over docetaxel alone in patients with chemotherapy resistant non-small cell lung cancer.
Objectives:
- Compare the survival of patients with non-small cell lung cancer treated with combination therapy with Pivanex and docetaxel vs. docetaxel alone
- Compare the time to disease progression, tumor responses, and safety profile of patients with non-small cell lung cancer treated with combination therapy with Pivanex and docetaxel vs. docetaxel alone
Outline: This is a randomized, open-label, multicenter study in patients with non-small cell lung cancer who have previously been treated with no more than one prior platinum containing chemotherapy regimen. Patients are stratified by ECOG performance status (0-1 vs. 2), response to prior platinum based chemotherapy (progression vs. CR/PR/SD) and prior taxane therapy (yes vs. no). Patients are randomized to 1 of 2 treatment arms.
- Arm A: Patients receive the combination of Pivanex intravenously on Days 1-3 and docetaxel intravenously on Day 4. Treatment repeats every 21 days until disease progression or treatment withdrawal.
- Arm B: Patients receive docetaxel intravenously on Day 1. Treatment repeats every 21 days until disease progression or treatment withdrawal.
Undersøgelsestype
Tilmelding
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Edinburgh, Det Forenede Kongerige, EH4 2XU
- University of Edinburgh, Edinburgh Cancer Centre
-
-
-
-
California
-
La Verne, California, Forenede Stater, 91750
- Wilshire Oncology Medical Group
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70115
- Hematology And Oncology Specialists, Llc
-
-
New York
-
Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center, Department of Oncology
-
Brooklyn, New York, Forenede Stater, 11235
- HemOnCare
-
-
North Carolina
-
Gastonia, North Carolina, Forenede Stater, 28054
- Gaston Hematology & Oncology Associates
-
-
-
-
-
New Delhi, Indien, 110 085
- Rajiv Gandhi Cancer Institute & Research Center
-
Thiruvananthapuram, Indien, 695 011
- Regional Cancer Centre
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Histologically or cytologically confirmed non-small cell lung cancer (NSCLC); Treatment with one prior platinum-based chemotherapy regimen (Eligible patients may include:
- Patients previously treated with adjuvant or neoadjuvant chemotherapy (must be completed within 6 months prior to randomization) or
- Patients who have received chemotherapy for advanced or metastatic lung cancer);
- Recurrent or progressive NSCLC (local, distant, or both) following initial chemotherapy);
- Measurable or non-measurable disease;
- Males and females, age => 18 years;
- Adequate renal function with creatinine => 1.5 mg/dl;
- Adequate liver function with alkaline phosphatase => 2.5 X upper limit of normal, SGOT, and SGPT => 1.5 X upper limit of normal; and total bilirubin => upper limit of normal;
- Adequate bone marrow function: platelets > 100,000/mm3, hemoglobin => 9 g/dL, and absolute neutrophil count (ANC) => 1,500 cells/mm3;
- Able to give informed consent;
- Discontinuation of previous surgery, radiation therapy or cancer chemotherapy at least four weeks prior to randomization (six weeks if a prior nitrosourea or mitomycin C), with recovery from treatment-associated toxicity;
- A predicted life expectancy of at least 12 weeks; and
- ECOG performance status of 0, 1, or 2.
Exclusion Criteria:
- Receipt of more than one chemotherapy regimen for NSCLC;
- A second malignancy within the last 5 years other than curatively treated carcinoma-in-situ or non-melanoma skin cancer;
- Pregnant or lactating females (Females of childbearing potential must have a negative pregnancy test and all male and female patients of reproductive potential must agree to use adequate birth control);
- Known HIV-positive patients;
- Acute medical problems, such as ischemic heart or lung disease or uncontrolled systemic infection;
- Patients with any underlying medical conditions or circumstance, which would contraindicate therapy with study treatment, affect compliance or impair evaluation of study endpoints;
- Patients receiving investigational agents within 30 days of the screening visit;
- Known allergy to reagents in the study;
- Prior docetaxel therapy;
- Symptomatic or untreated brain metastases (Patients with brain metastases are eligible if they are clinically and neurologically stable for > 4 weeks since therapy (radiation therapy, radiosurgery/gamma knife; surgical resection) as determined by the investigator and either off corticosteroids or on a stable dose of corticosteroids).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Neoplasmer, kirtel og epitel
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Karcinom
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Docetaxel
Andre undersøgelses-id-numre
- TTP-200-03-01
- NSCLC Clincal Trial
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Karcinom, ikke-småcellet lunge
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
National Cancer Institute (NCI)AfsluttetIldfast malignt fast neoplasma | Tilbagevendende malignt fast neoplasma | Metastatisk malignt fast neoplasma | Uoprettelig fast neoplasma | Tilbagevendende småcellet lungekarcinom | Stadie IIIA Lunge småcellet karcinom AJCC v7 | Stadie IIIB Lunge småcellet karcinom AJCC v7 | Stadie IV lunge småcellet... og andre forholdForenede Stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeSezary syndrom | Refraktær T-celle non-Hodgkin lymfom | Merkel cellekarcinom | Anaplastisk storcellet lymfom, ALK-positivt | Ekstramammær Paget sygdom | Tilbagevendende T-celle non-Hodgkin lymfom | Tilbagevendende moden T-celle og NK-celle non-Hodgkin lymfom | Refraktær moden T-celle og NK-celle non-Hodgkin... og andre forholdForenede Stater
Kliniske forsøg med Docetaxel
-
Nereus Pharmaceuticals, Inc.AfsluttetKræftForenede Stater, Australien, Indien, Chile, Brasilien, Argentina
-
Tianjin Medical University Cancer Institute and...Rekruttering
-
Zhuhai Beihai Biotech Co., LtdAfsluttetFaste tumorer | Bioækvivalens | DocetaxelIndien
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaAfsluttetIkke-småcellet lungekræft (NSCLC)Kina
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical... og andre samarbejdspartnereUkendt
-
Optimal Health ResearchAfsluttetBrystkræft | Lungekræft | ProstatakræftForenede Stater
-
Arog Pharmaceuticals, Inc.Trukket tilbageKarcinom, ikke-småcellet lunge
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRekrutteringKastrationsresistent prostatakræftAustralien
-
SanofiAfsluttet
-
SanofiAfsluttetLungeneoplasmerFrankrig, Holland, Spanien, Kalkun, Belgien, Finland, Italien, Det Forenede Kongerige